ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,292Medicare Part D Prescriptions Filled, Including Refills

Rank: 32 out of 623

$502K Total Retail Price of All Prescriptions

Rank: 38 out of 623

200 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
81% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 200 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 7,233 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$61 was the average price of a prescription from this provider, compared to $66 among peers.

Prescriptions per Patient

41 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
AMLODIPINE BESYLATE 316 291 1 3
LISINOPRIL 263 236 2 1
LEVOTHYROXINE SODIUM 246 228 3 4
TRAMADOL HCL 211 198 4 15
CITALOPRAM HBR 201 188 5 21
FUROSEMIDE 185 173 6 5
RISPERIDONE 161 137 7 49
DONEPEZIL HCL 159 159 8 27
OMEPRAZOLE 157 140 9 7
METOPROLOL TARTRATE 154 137 10 9
SIMVASTATIN 138 83 11 2
JANTOVEN 133 131 12 54
HYDROCHLOROTHIAZIDE 121 112 13 8
NAMENDA 121 121 13 47
CARVEDILOL 112 112 15 32
MIRTAZAPINE 109 109 16 31
RANITIDINE HCL 109 105 16 23
TRAZODONE HCL 104 92 18 36
DIOVAN 100 88 19 48
OXCARBAZEPINE 97 84 20 226
LOVASTATIN 93 84 21 25
CLONIDINE HCL 93 79 21 55
CARBIDOPA-LEVODOPA 92 77 23 88
METOPROLOL SUCCINATE 91 86 24 13
CLOPIDOGREL 88 78 25 34
PANTOPRAZOLE SODIUM 88 76 25 26
METFORMIN HCL 87 59 27 6
LOSARTAN POTASSIUM 86 86 28 16
LIDODERM 85 85 29 82
ISOSORBIDE MONONITRATE ER 82 67 30 64
NOVOLOG 80 70 31 75
LACTULOSE 80 60 31 67
HYDRALAZINE HCL 78 65 33 70
DIVALPROEX SODIUM 77 41 34 77
GABAPENTIN 75 62 35 18
PREDNISONE 72 72 36 40
QUETIAPINE FUMARATE 69 50 37 51
LANTUS 69 51 37 41
SERTRALINE HCL 68 68 39 20
ATORVASTATIN CALCIUM 67 62 40 10
MUPIROCIN 60 58 41 146
SULFAMETHOXAZOLE-TRIMETHOPRIM 60 58 41 78
NYSTATIN-TRIAMCINOLONE 60 60 41 209
PRAVASTATIN SODIUM 58 58 44 11
DIGOXIN 57 57 45 63
PLAVIX 57 52 45 46
LEVETIRACETAM 54 42 47 83
VENLAFAXINE HCL 52 52 48 203
ATENOLOL 52 52 48 12
POTASSIUM CHLORIDE 51 39 50 24
HYDROXYZINE HCL 50 46 R 51 187
TAMSULOSIN HCL 50 38 51 35
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 9, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.